Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Phase-1b-Studie zur Untersuchung der Sicherheit, Verträglichkeit und Pharmakokinetik von ABBV-CLS-7262 bei Patienten mit verschwindender weißer Substanz

16. Oktober 2026 aktualisiert von: Calico Life Sciences LLC

Eine Open-Label-Studie der Phase 1b zur Bewertung der Sicherheit, Verträglichkeit und Pharmakokinetik nach der Verabreichung von ABBV-CLS-7262 bei erwachsenen Probanden mit Vanishing White Matter Disease

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease.

Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Quebec
      • Montreal, Quebec, Kanada, H3H2L9
        • Rekrutierung
        • McGill University Health Centre - Glen Site
    • North Holland
      • Amsterdam, North Holland, Niederlande, 1081 HV
        • Rekrutierung
        • Amsterdam UMC, locatie VUmc /ID# 270955
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Rekrutierung
        • Massachusetts General Hospital /ID# 270960
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84112-5339
        • Rekrutierung
        • University of Utah /ID# 255624

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Monate und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Males and females ≥18 y of age (Cohort 1 and Cohort 1b - adults), ≥12 y and <18 y of age (Cohort 2 - adolescents), ≥6 y and <12 y of age (Cohort 3 - children), and ≥6 mos and <6 y of age (Cohort 4 - children [≥1 y and <6 y of age] and infants [≥6 mos and <1 y of age]) at the time of Screening.

  2. Subject must have VWM disease defined as:

    • A clinical diagnosis by a physician experienced in the assessment of VWM disease, AND
    • A molecular diagnosis of VWM disease (Note: Subjects who can provide a verified laboratory report of previously performed VWM molecular diagnosis, including the specific mutation(s), will not be required to reconfirm diagnosis before Screening), AND
    • A magnetic resonance imaging (MRI) presentation consistent with VWM disease, as assessed by a neuroradiologist or by a physician experienced in the assessment of VWM disease except for presymptomatic homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (requires approval from Sponsor).
  3. Subject must have a designated caregiver who is able to complete the respective caregiver ce ntered assessments. The caregiver must be consistently present at visits, including telehealth visits, to report on symptoms and comply with the protocol. The caregiver must be willing to provide informed consent.

  4. Subject is willing and able to give informed consent. Where local regulations permit inclusion of participants deemed not able to provide informed consent, a legally authorized representative (LAR) must provide informed consent on the subject's behalf, and the subject must provide assent, in accordance with the local regulations, guidelines, and Institutional Review Board (IRB), or Independent Ethics Committee (IEC). If the subject becomes cognitively impaired (diminished capacities) during the study and is unable to provide informed consent, the subject should be discontinued from the study unless local regulations permit inclusion of participants deemed not able to provide informed consent. In such case, a LAR must provide informed consent on behalf of the subject and the subject must provide assent as per local regulations, guidelines, and IRB or IEC. Careful consideration will be given to ensure that cognitive impairment/diminished capacity does not limit the subject's right to withdraw from the study. The LAR and the caregiver can be the same person.

  5. Subjects in Cohorts 1, 1b, 2, and 3 must meet criteria a and at least 1 of the other criteria listed below (b or c):

    • Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease
    • Motor criteria as defined below:

    All age groups:

    Inability to walk 10 or more steps with or without light support of 2 hands

    - Cognitive criteria as defined below (Note: Subjects are not required to complete testing if they meet the motor criteria or if they are able to provide source documentation of prior cognitive testing performed by a qualified psychologist and meeting eligibility criteria obtained in the past 12 months):

    Adults and adolescents ≥16 y of age must have:

    A perceptual reasoning index <50 (Wechsler Adult Intelligence Scale, fourth edition [WAIS-IV])

    Adolescents and children ≥6 y and <16 y of age must have:

    A visuospatial reasoning index <50 (block design, visual puzzles, Wechsler Intelligence Scale for Children performance, fifth edition [WISC-V]) AND A fluid reasoning index <50 (matrix reasoning, figure weights, WISC-V). Note: At the Sponsor's discretion, pediatric subjects <16 y of age who are unable to complete the subtests for calculating BOTH indices of the WISC-V due to functional impairment (e.g., due to fine motor or visual impairment) may meet inclusion criteria by a score <50 on either the visuospatial reasoning index OR the fluid reasoning index of the WISC-V.

    Pediatric subjects in Cohort 4 must meet both criteria a and b below, or criterion c:

    Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease

    Motor criteria as defined below:

    More than minimal head control as demonstrated by:

    While in prone position, the subject can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

  6. All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study and until 30 days after the final dose of study drug.

  7. All female subjects who are sexually active and of childbearing potential must agree to use an acceptable contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

  8. Canada-specific Cohort 5: Male and female infant subjects between 0 mos and <6 mos of age at the time of Screening.

  9. Canada-specific Cohort 5: Subject body weight ≥5 kg at the time of the Baseline visit. The screening period can be extended by up to 30 days to ensure that this minimum weight is met at the Baseline visit.

  10. Canada-specific Cohort 5: Homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation(s) with known imminent risk of significant clinical decline or death (the Sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).

An MRI presentation consistent with VWM disease is not required for Cohort 5. Exclusion Criteria

  1. Pediatric subjects ≥6 mos and <6 y of age must not be on any form of respiratory support at the time of Screening.
  2. Subject who has any clinically significant electrocardiogram (ECG) abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >450 msec for adult males, >470 msec for adult females, or >450 msec for adolescents ≥12 y and <18 y of age (Cohort 2) and children ≥6 y and <12 y of age (Cohort 3), or >414 msec for infants and children ≥0.5 y and <6 y of age (Cohort 4).
  3. Subject with current or history of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease (other than VWM) that would preclude administration of FGT or safe participation in the study Abnormal adrenal function, defined as confirmed abnormal random cortisol or ACTH at Screening (see Section 7.2.8 for cortisol and ACTH thresholds) Participants may undergo repeat cortisol and ACTH testing once, in order to establish normal adrenal function. If repeat cortisol and/or ACTH testing is abnormal, at the Investigator's discretion, the participant may undergo cosyntropin stimulation testing to establish normal adrenal function to meet eligibility criteria.
  4. Subject who has suicidal ideation at the Screening Visit (V1). Prior medical history and/or Columbia-Suicide Severity Rating Scale (C-SSRS) may be used to inform the Investigator's decision.
  5. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
  6. Seizure disorder not considered adequately controlled by the Investigator within the 6 months preceding Screening.
  7. Subject who, in the opinion of the Investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints (e.g., due to severe comorbid conditions or severity of VWM disease).
  8. Subjects who are pregnant, breastfeeding, or providing breast milk. Note: Infant subjects are permitted to receive breast milk from a non-participant mother or caregiver (who is not receiving the study intervention).
  9. Canada-specific Cohort 5: Subjects between 0 mos and <6 mos of age must not be on any form of respiratory support at the time of Screening.
  10. Canada-specific Cohort 5: Subject who has any clinically significant ECG abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >414 msec for infants between 0 mos and <6 mos of age

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Fosigotifator - Cohort 1

Cohort 1: VWM adults >= 18 years.

Oral Use

Andere Namen:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 1b

Cohort 1b: VWM adults >= 18 years.

Oral Use

Andere Namen:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 2

Cohort 2: VWM children>= 12 y and <18 years.

Oral Use

Andere Namen:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 3

Cohort 3: VWM children >= 6 y and <12 years.

Oral Use

Andere Namen:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 4

Cohort 4: VWM children >= 6 months and <6 years.

Oral Use

Andere Namen:
  • ABBV-CLS-7262
Experimental: Fosigotifator - Cohort 5 (Canada Only)

VWM Children >0 and <6 months

Oral Use

Andere Namen:
  • ABBV-CLS-7262

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Treatment-Emergent Adverse Events
Zeitfenster: Baseline up to Approximately Day 28

Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Day 28
Number of Participants with Change in Vital Signs
Zeitfenster: Baseline up to Approximately Day 28

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in ECG
Zeitfenster: Baseline up to Approximately Day 28

Number of Participants with Change in ECG will be assessed.

Baseline up to Approximately Day 28
Number of Participants with Change in Clinical Laboratory Tests
Zeitfenster: Baseline up to Approximately Day 28

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to Approximately Day 28
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Zeitfenster: Baseline up to Approximately Day 28

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to Approximately Day 28
Plasma Concentration of Fosigotifator
Zeitfenster: Baseline up to approximately Week 96

Maximum Plasma Concentration [Cmax]

Baseline up to approximately Week 96
Time to Cmax (Tmax) of Fosigotifator
Zeitfenster: Baseline up to approximately Week 96

Tmax of Fosigotifator

Baseline up to approximately Week 96
Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator
Zeitfenster: Baseline up to approximately Week 96

AUC0-24h of Fosigotifator

Baseline up to approximately Week 96
Trough Concentration (Ctrough) of Fosigotifator
Zeitfenster: Baseline up to approximately Week 96

Ctrough of Fosigotifator

Baseline up to approximately Week 96
Terminal Elimination Half-Life (t1/2) of Fosigotifator
Zeitfenster: Baseline up to approximately Week 96

t1/2 of Fosigotifator

Baseline up to approximately Week 96

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Treatment-Emergent Adverse Events
Zeitfenster: Baseline up to Approximately Week 197

Number of patients with treatment-related adverse events as assessed by CTCAE v4.03

Baseline up to Approximately Week 197
Number of Participants with Change in Vital Signs
Zeitfenster: Baseline up to approximately Week 197

Number of Participants with Change in Vital Signs will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in ECG
Zeitfenster: Baseline up to approximately Week 197

Number of Participants with Change in ECG will be assessed.

Baseline up to approximately Week 197
Number of Participants with Change in Clinical Laboratory Tests
Zeitfenster: Baseline up to approximately Week 197

Number of participants with change in clinical laboratory tests will be assessed.

Baseline up to approximately Week 197
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Zeitfenster: Baseline up to approximately Week 197

The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Baseline up to approximately Week 197
Number of Participants with Change in Magnetic Resonance Imaging (MRI)
Zeitfenster: Baseline up to approximately Week 192

Change in Brain Magnetic Resonance Imaging (MRI) associated with adverse events.

Baseline up to approximately Week 192

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. März 2023

Primärer Abschluss (Geschätzt)

1. November 2027

Studienabschluss (Geschätzt)

1. Oktober 2035

Studienanmeldedaten

Zuerst eingereicht

23. Februar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. März 2023

Zuerst gepostet (Tatsächlich)

7. März 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • M23-523
  • 2023-505704-30-00 (Andere Kennung: EU CT)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .